Weight gain risk factor assessment checklist: Overview and recommendation for use

Neuroendocrinology Letters

Volumn 32, Issue 2, 2011, Pages 199-205

  Treuer, Tamás ^a   Pendlebury, John ^b   Lockman, Hazlin ^c   Bushe, Chris ^d   Karagianis, Jamie ^d   Raskin, Joel ^d   Lipkovich, Ilya ^d  

^a Lilly Hungaria Kft   (Hungary)

^b Ramsgate House   (United Kingdom)

^c UNIVERSITY OF MALAYA   (Malaysia)

^d ELI LILLY AND COMPANY   (United States)

Author keywords

Antipsychotics; Bipolar disorder; Checklist; Schizophrenia; Weight gain

Indexed keywords

NEUROLEPTIC AGENT; OLANZAPINE;

16 ITEM WEIGHT GAIN RISK FACTOR CHECKLIST; APPETITE; ARTICLE; BIPOLAR MANIA; BODY MASS; CALORIC INTAKE; CHECKLIST; CLINICAL ASSESSMENT; COMORBIDITY; CONTROLLED STUDY; DRUG RESPONSE; EATING HABIT; HOUSING; HUMAN; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MEDICAL RESEARCH; OUTCOME ASSESSMENT; PATIENT MONITORING; PHYSICAL ACTIVITY; PRACTICE GUIDELINE; PREDICTIVE VALIDITY; PREDICTOR VARIABLE; PUBLISHING; RISK ASSESSMENT; RISK FACTOR; SATISFACTION; SCHIZOPHRENIA; SIDE EFFECT; SOCIAL BEHAVIOR; TREATMENT RESPONSE; WEIGHT GAIN;

EID: 80051692353     PISSN: 0172780X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (51)

1. Saha S, Chant D, McGrath J (2007) A systematic review of mortality in schizophrenia: is the differential mortality gap worsening over time? Arch Gen Psychiatry. 64: 1123-1131.
2. Kisely S, Campbell LA, Wang Y (2009) Treatment of ischaemic heart disease and stroke in individuals with psychosis under universal healthcare. Br J Psychiatry. 195: 545-550.
3. Solutions for Wellness: Personalized Program for Healthy Living (2010) Available at: http://www.solutionsforwellness.info/.Accessed 29 December 2010.
4. Treuer T, Hoffmann VP, Chen AK, Irimia V, Ocampo M, Wang G, et al (2009) Factors associated with weight gain during olanzapine treatment in patients with schizophrenia or bipolar disorder: results from a six-month prospective, multinational, observational study. World J Biol Psychiatry. 10: 729-740.
5. Kahn RS, Fleischhacker WW, Boter H, Davidson M, Vergouwe Y, Keet IP, et al (2008) Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomised clinical trial. Lancet. 371: 1085-1097. (Pubitemid 351418005)
6. Pendlebury J, Bushe CJ, Wildgust HJ, Holt RI (2007) Long-term maintenance of weight loss in patients with severe mental illness through a behavioural treatment programme in the UK. Acta Psychiatr Scand. 115: 286-294. (Pubitemid 46425749)
7. Winters BD, Gurses AP, Lehmann H, Sexton JB, Rampersad CJ, Pronovost PJ (2009) Clinical review: checklists - translating evidence into practice. Crit Care. 13: 210.
8. Holt RI, Pendlebury J, Wildgust HJ, Bushe CJ (2010) Intentional weight loss in overweight and obese patients with severe mental illness: 8-year experience of a behavioral treatment program. J Clin Psychiatry. 71: 800-805.
9. Bushe CJ, McNamara D, Haley C, McCrossan MF, Devitt P (2008) Weight management in a cohort of Irish inpatients with serious mental illness (SMI) using a modular behavioural programme. A preliminary service evaluation. BMC Psychiatry. 15: 76.
10. Poulin MJ, Chaput JP, Simard V, Vincent P, Bernier J, Gauthier Y (2007) Management of antipsychotic-induced weight gain: prospective naturalistic study of the effectiveness of a supervised exercise programme. Aust N Z J Psychiatry. 41: 980-989. (Pubitemid 350120827)
11. Porsdal V, Beal C, Kleivenes OK, Martinsen EW, Lindström E, Nilsson H, Svanborg P (2010) The Scandinavian Solutions for Wellness study - a two-arm observational study on the effectiveness of lifestyle intervention on subjective well-being and weight among persons with psychiatric disorders. BMC Psychiatry. 10: 42.
12. Tiihonen J, Lönnqvist J, Wahlbeck K, Klaukka T, Niskanen L, Tanskanen A, Haukka J (2009) 11-year follow-up of mortality in patients with schizophrenia: a population-based cohort study (FIN11 study). Lancet. 374: 620-627.
13. Bushe C, Sniadecki J, Bradley AJ, Poole Hoffmann V (2010) Comparison of metabolic and prolactin variables from a six-month randomised trial of olanzapine and quetiapine in schizophrenia. J Psychopharmacol. 24: 1001-1009.
14. Crompton D, Groves A, McGrath J (2010) What can we do to reduce the burden of avoidable deaths in those with serious mental illness? Epidemiol Psichiatr Soc. 19: 4-7.
15. Perez-Iglesias R, Crespo-Facorro B, Martinez-Garcia O, Ramirez-Bonilla ML, Alvarez-Jimenez M, Pelayo-Teran JM, et al (2008) Weight gain induced by haloperidol, risperidone and olanzapine after 1 year: findings of a randomized clinical trial in a drug-naïve population. Schizophr Res. 99: 13-22. (Pubitemid 351255577)
16. Remington G (2006) Schizophrenia, antipsychotics, and the metabolic syndrome: is there a silver lining? Am J Psychiatry. 163: 1132-1134.
17. Millen BA, Campbell GM, Beasley CM (2010) Weight changes over time in adults treated with the oral or depot formulations of olanzapine: a pooled analysis of 86 clinical trials. J Psychopharmacol. doi:10.1177/0269881110370505.
18. Enger C, Weatherby L, Reynolds RF, Glasser DB, Walker AM (2004) Serious cardiovascular events and mortality among patients with schizophrenia. J Nerv Ment Dis. 192: 19-27. (Pubitemid 38101693)
19. Osborn DP, Levy G, Nazareth I, Petersen I, Islam A, King MB (2007) Relative risk of cardiovascular and cancer mortality in people with severe mental illness from the United Kingdom's General Practice Rsearch Database. Arch Gen Psychiatry. 64: 242-249. (Pubitemid 46220782)
20. Dean CE, Thuras PD (2009) Mortality and tardive dyskinesia: long-term study using the US National Death Index. Br J Psychiatry. 194: 360-364.
21. Strom BL, Faich GA, Reynolds RF, Eng SM, D'Agostino RB, Ruskin JN, et al (2008) The Ziprasidone Observational Study of Cardiac Outcomes (ZODIAC): design and baseline subject characteristics. J Clin Psychiatry. 69: 114-121. (Pubitemid 351282004)
22. Strom BL, Eng SM, Faich G, Reynolds RF, D'Agostino RB, Ruskin JN, et al (2010) Comparative Mortality Associated With Ziprasidone and Olanzapine in Real-World Use Among 18,154 Patients With Schizophrenia: The Ziprasidone Observational Study of Cardiac Outcomes (ZODIAC). Am J Psychiatry. doi:10.1176/appi.ajp.2010.08040484.
23. Bushe C, Haddad P, Peveler R, Pendlebury J (2005) The role of life-style interventions and weight management in schizophrenia. J Psychopharmacol. 19(6 Suppl): 28-35. (Pubitemid 44567856)
24. Bushe C, Paton C (2005) The potential impact of antipsychotics on lipids in schizophrenia: is there enough evidence to confirm a link? J Psychopharmacol. 19(6 Suppl): 76-83.
25. Spelman LM, Walsh PI, Sharifi N, Collins P, Thakore JH (2007) Impaired glucose tolerance in first-episode drug-naive patients with schizophrenia. Diabet Med. 24: 481-485. (Pubitemid 46669314)
26. Koivukangas J, Tammelin T, Kaakinen M, Mäki P, Moilanen I, Taanila A, Veijola J (2010) Physical activity and fitness in adolescents at risk for psychosis within the Northern Finland 1986 Birth Cohort. Schizophr Res. 116: 152-158.
27. Treuer T, Karagianis J, Hoffmann VP (2008) Can increased food intake improve psychosis? A brief review and hypothesis. Review. Curr Mol Pharmacol. 1: 270-272.
28. Case M, Treuer T, Karagianis J, Hoffmann VP (2010) The potential role of appetite in predicting weight changes during treatment with olanzapine. BMC Psychiatry. 10: 72.
29. Lipkovich I, Jacobson JG, Hardy TA, Hoffmann VP (2008) Early evaluation of patient risk for substantial weight gain during olanzapine treatment for schizophrenia, schizophreniform, or schizoaffective disorder. BMC Psychiatry. 8: 78.
30. Lipkovich I, Jacobson JG, Caldwell C, Hoffmann VP, Kryzhanovskaya L, Beasley CM (2009) Early predictors of weight gain risk during treatment with olanzapine: analysis of pooled data from 58 clinical trials. Psychopharmacol Bull. 42: 23-39.
31. Basson BR, Kinon BJ, Taylor CC, Szymanski KA, Gilmore JA, Tollefson GD (2001) Factors influencing acute weight change in patients with schizophrenia treated with olanzapine, haloperidol, or risperidone. J Clin Psychiatry. 62: 231-238. (Pubitemid 32428761)
32. Lipkovich I, Citrome L, Perlis R, Deberdt W, Houston JP, Ahl J, et al (2006) Early predictors of substantial weight gain in bipolar patients treated with olanzapine. J Clin Psychopharmacol. 26: 316-320.
33. Strassnig M, Miewald J, Keshavan M, Ganguli R (2007) Weight gain in newly diagnosed first-episode psychosis patients and healthy comparisons: one-year analysis. Schizophr Res. 93: 90-98. (Pubitemid 46817931)
34. Smith E, Rothschild AJ, Heo M, Peasley-Miklus C, Caswell M, Papademetriou E, et al (2008) Weight gain during olanzapine treatment for psychotic depression: effects of dose and age. Int Clin Psychopharmacol. 23: 130-137. (Pubitemid 351535904)
35. Kinon BJ, Basson BR, Gilmore JA, Tollefson GD (2001) Long-term olanzapine treatment: weight change and weight-related health factors in schizophrenia. J Clin Psychiatry. 62: 92-100. (Pubitemid 32199865)
36. Kinon BJ, Kaiser CJ, Ahmed S, Rotelli MD, Kollack-Walker S (2005) Association between early and rapid weight gain and change in weight over one year of olanzapine therapy in patients with schizophrenia and related disorders. J Clin Psychopharmacol. 25: 255-258. (Pubitemid 40685790)
37. Saddichha S, Ameen S, Akhtar S (2007) Predictors of antipsychotic-induced weight gain in first-episode psychosis: conclusions from a randomised, double-blind, controlled prospective study of olanzapine, risperidone, and haloperidol. J Clin Psychopharmacol. 28: 27-31.
38. Ujike H, Nomura A, Morita Y, Morio A, Okahisa Y, Kotaka T, et al (2008) Multiple genetic factors in olanzapine-induced weight gain in schizophrenia patients: a cohort study. J Clin Psychiatry. 69: 1416-1422.
39. Poyurovsky M, Fuchs C, Pashinian A, Levi A, Faragian S, Maayan R, et al (2007) Attenuating effect of reboxetine on appetite and weight gain in olanzapine-treated schizophrenia patients: a double-blind, placebo-controlled study. Psychopharmacology. 192: 441-448. (Pubitemid 46701583)
40. Gothelf D, Falk B, Singer P, Kairi M, Phillip M, Zigel L, et al (2002) Weight gain associated with increased food intake and low habitual activity levels in male adolescent schizophrenic inpatients treated with olanzapine. Am J Psychiatry. 159: 1055-1057. (Pubitemid 34586957)
41. Zipursky RB, Gu H, Green AI, Perkins DO, Tohen MF, McEvoy JP, et al (2005) Course and predictors of weight gain in people with first-episode psychosis treated with olanzapine or haloperidol. Br J Psychiatry. 187: 537-543.
42. Gebhardt S, Haberhausen M, Heinzel-Gutenbrunner M, Gebhardt N, Remschmidt H, Krieg JC, et al (2009) Antipsychotic-induced body weight gain: predictors and a systematic categorization of the long-term weight course. J Psychiatr Res. 43: 620-626.
43. Saravane D, Feve B, Frances Y, Corruble E, Lancon C, Chanson P, et al (2009) Drawing up guidelines for the attendance of physical health of patients with severe mental illness. Encephale. 35: 330-339.
44. European Medicines Agency. Summary of Product Characteristics, 2010. EMA web site. Available at: http://www.ema.europa.eu/docs/en-GB/document-library/ EPAR---Product-Information/human/000115/WC500055207.pdf. Accessed February 24, 2011.
45. Taylor DM, McAskill R (2000) Atypical antipsychotics and weight gain - a systematic review. Acta Psychiatr Scand. 101: 416-432. (Pubitemid 30365564)
46. Allison DB, Casey DE (2001) Antipsychotic-induced weight gain: a review of the literature. J Clin Psychiatry. 62 (Suppl 7): 22-31. (Pubitemid 32402182)
47. McIntyre RS, Trakas K, Lin D, Balshaw R, Hwang P, Robinson K, et al (2003) Risk of weight gain associated with antipsychotic treatment: results from the Canadian National Outcomes Measurement Study in Schizophrenia. Can J Psychiatry. 48: 689-694.
48. Bushe CJ, Taylor M, Mathew M (2007) Intramuscular Olanzapine - a UK case series of early cases. Ann Gen Psychiatry. 6: 11.
49. Hoffmann PV, Ahl J, Meyers A, Schuh L, Shults KS, Collins DM, et al (2005) Wellness intervention for patients with serious and persistent mental illness. J Clin Psychiatry. 66: 1576-1579. (Pubitemid 43068698)
50. Hoffmann PV, Bushe C, Meyers AL, Greenwood T, Benzing L, Ahl J (2008) A wellness intervention program for patients with mental illness: self-reported outcomes. Prim Care Companion J Clin Psychiatry. 10: 329-331.
51. Stauffer VL, Lipkovich I, Hoffmann VP, Heinloth AN, McGregor HS, Kinon BJ (2009) Predictors and correlates for weight changes in patients co-treated with olanzapine and weight mitigating agents; a post-hoc analysis. BMC Psychiatry. 9: 12.